SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jake burns who wrote (1140)11/7/1998 3:50:00 PM
From: Bruce H. Becker  Read Replies (1) of 1510
 
Hi Jake

Here is an article with the name of RA drug. Know that IMNR has applied for a name for the drug, but there is no one name that is approved as of yet.

Carlsbad-based Immune Response Corp. began an open-label,long-term follow-up clinical trial of its therapeutic vaccine for rheumatoid arthritis. The Carlsbad-based company said the trial, which is designed to enroll up to 350 patients, will provide the vaccine to patients who have completed the current Phase IIb trial and wish to continue treatment.

The trial seeks to evaluate the long-term safety and activity of the drug. The IR501 vaccine, which is administered via intramuscular injection, is designed to turn off the specific immune system cells that the company believes cause rheumatoid arthritis.

Bruce
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News